FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489304851> ?p ?o ?g. }

• W1489304851 endingPage "232" @default.
• W1489304851 startingPage "221" @default.
• W1489304851 abstract "What's known on the subject? and What does the study add? Studies comparing adverse effects after different treatment methods are few and lack information on additional treatment and cancer relapse. Some US studies have provided population-based estimates on adverse effects, however, figures from Europe are most often based on mono-institutional experience or multicentre studies from high-volume university-affiliated hospitals with selected patient populations. Few studies have investigated the relationship between presence of urinary, bowel or sexual dysfunction and global quality of life (QoL). This population-based study investigated real-life practice with regard to prostate cancer in men who were potential candidates for curative treatment, based on high-quality national registry data. Treatment groups of recurrence-free men who completed their treatment or who received no cancer treatment were measured as to adverse effects, global QoL and the association between them. The study shows that each treatment method is associated with distinct patterns of urinary, bowel and sexual dysfunction and that irritative–obstructive urinary symptoms are associated with increased risk of low global QoL. This large survey also investigates the use of medication for erectile dysfunction and the relationship between such use and global QoL. Objectives To provide population-based estimates of typical adverse effects (AEs), e.g. urinary, bowel and sexual dysfunction, in patients with non-metastatic recurrence-free prostate cancer (PCa) by curative treatment method, including no treatment. To describe associations between typical AEs and global quality of life (QoL) and to study patients' use of medication for erectile dysfunction (EDmed) and the relationship between such use and global QoL. Patients and Methods In October 2006 a national population-based sample of PCa survivors diagnosed in 2004 was invited to a postal survey focusing on treatment-related AEs and global QoL, 12–32 months after treatment start. All had completed their initial treatment. In the present study, 771 compliers were categorized into four groups of localized or locally advanced PCa related to the treatment they completed: (i) no treatment; (ii) radical prostatectomy (RP); (iii) radiotherapy (RAD) without hormones; and (iv) RAD with hormone therapy of 3–24 months duration. Measurement of AEs was restricted to function, using selected items from the 50-item Expanded Prostate Cancer Index Composite and the Brief Sexual Function Inventory among others, whereas global QoL was measured with the 12-item short-form health survey. National prescription data enabled assessment of adjuvant hormone application and EDmed use. Results Men who had undergone RP reported more urinary incontinence (24%) than the other treatment groups, but had the lowest level of moderate/severe urinary irritative–obstructive symptoms. Men from the ‘no treatment’ group had the highest level of moderate/severe irritative–obstructive urinary symptoms. Men who had undergone RAD reported higher levels of irritative intestinal symptoms and faecal leakage compared with the RP group and the no treatment group. In all treatment groups, poor sexual drive and poor erectile function were common AEs, with men treated with RP reporting the highest prevalence of poor erectile function (89%). Presence of irritative–obstructive urinary symptoms and poor sexual drive were independently associated with low global QoL in multivariate analyses. Fifty percent of the study group had used EDmed after treatment start, but only 47% of them were still using EDmed at the time of the survey. Use of EDmed was not significantly associated with global QoL. Conclusions PCa survivors after curative treatment, but also patients without any anticancer therapy, report high levels of urinary and sexual AEs. Irritative–obstructive urinary symptoms and poor sexual drive were significantly associated with low global QoL, whereas erectile function and use of EDmed were not." @default.
• W1489304851 created "2016-06-24" @default.
• W1489304851 creator A5022350013 @default.
• W1489304851 creator A5038328418 @default.
• W1489304851 creator A5055908859 @default.
• W1489304851 creator A5062805582 @default.
• W1489304851 creator A5085074995 @default.
• W1489304851 date "2012-06-06" @default.
• W1489304851 modified "2023-10-16" @default.
• W1489304851 title "A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer" @default.
• W1489304851 cites W1488498119 @default.
• W1489304851 cites W1846391742 @default.
• W1489304851 cites W1966372077 @default.
• W1489304851 cites W1968285708 @default.
• W1489304851 cites W1971102738 @default.
• W1489304851 cites W1971486551 @default.
• W1489304851 cites W1973371612 @default.
• W1489304851 cites W1979842176 @default.
• W1489304851 cites W1982330837 @default.
• W1489304851 cites W2031931231 @default.
• W1489304851 cites W2034296474 @default.
• W1489304851 cites W2036650597 @default.
• W1489304851 cites W2040008722 @default.
• W1489304851 cites W2040099375 @default.
• W1489304851 cites W2045237796 @default.
• W1489304851 cites W2050302634 @default.
• W1489304851 cites W2052690305 @default.
• W1489304851 cites W2054884412 @default.
• W1489304851 cites W2055968506 @default.
• W1489304851 cites W2068539233 @default.
• W1489304851 cites W2072551903 @default.
• W1489304851 cites W2083176336 @default.
• W1489304851 cites W2094008048 @default.
• W1489304851 cites W2095919110 @default.
• W1489304851 cites W2101001966 @default.
• W1489304851 cites W2101403968 @default.
• W1489304851 cites W2105410805 @default.
• W1489304851 cites W2106162902 @default.
• W1489304851 cites W2107601840 @default.
• W1489304851 cites W2110488527 @default.
• W1489304851 cites W2111521308 @default.
• W1489304851 cites W2132697170 @default.
• W1489304851 cites W2137282952 @default.
• W1489304851 cites W2138987578 @default.
• W1489304851 cites W2147991258 @default.
• W1489304851 cites W2172151487 @default.
• W1489304851 cites W2993539218 @default.
• W1489304851 cites W4239075713 @default.
• W1489304851 doi "https://doi.org/10.1111/j.1464-410x.2012.11198.x" @default.
• W1489304851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22672151" @default.
• W1489304851 hasPublicationYear "2012" @default.
• W1489304851 type Work @default.
• W1489304851 sameAs 1489304851 @default.
• W1489304851 citedByCount "41" @default.
• W1489304851 countsByYear W14893048512013 @default.
• W1489304851 countsByYear W14893048512014 @default.
• W1489304851 countsByYear W14893048512015 @default.
• W1489304851 countsByYear W14893048512016 @default.
• W1489304851 countsByYear W14893048512017 @default.
• W1489304851 countsByYear W14893048512018 @default.
• W1489304851 countsByYear W14893048512020 @default.
• W1489304851 countsByYear W14893048512023 @default.
• W1489304851 crossrefType "journal-article" @default.
• W1489304851 hasAuthorship W1489304851A5022350013 @default.
• W1489304851 hasAuthorship W1489304851A5038328418 @default.
• W1489304851 hasAuthorship W1489304851A5055908859 @default.
• W1489304851 hasAuthorship W1489304851A5062805582 @default.
• W1489304851 hasAuthorship W1489304851A5085074995 @default.
• W1489304851 hasConcept C121608353 @default.
• W1489304851 hasConcept C126322002 @default.
• W1489304851 hasConcept C143998085 @default.
• W1489304851 hasConcept C159110408 @default.
• W1489304851 hasConcept C197934379 @default.
• W1489304851 hasConcept C2778093883 @default.
• W1489304851 hasConcept C2779929075 @default.
• W1489304851 hasConcept C2779951463 @default.
• W1489304851 hasConcept C2780192828 @default.
• W1489304851 hasConcept C2908647359 @default.
• W1489304851 hasConcept C71924100 @default.
• W1489304851 hasConcept C99454951 @default.
• W1489304851 hasConceptScore W1489304851C121608353 @default.
• W1489304851 hasConceptScore W1489304851C126322002 @default.
• W1489304851 hasConceptScore W1489304851C143998085 @default.
• W1489304851 hasConceptScore W1489304851C159110408 @default.
• W1489304851 hasConceptScore W1489304851C197934379 @default.
• W1489304851 hasConceptScore W1489304851C2778093883 @default.
• W1489304851 hasConceptScore W1489304851C2779929075 @default.
• W1489304851 hasConceptScore W1489304851C2779951463 @default.
• W1489304851 hasConceptScore W1489304851C2780192828 @default.
• W1489304851 hasConceptScore W1489304851C2908647359 @default.
• W1489304851 hasConceptScore W1489304851C71924100 @default.
• W1489304851 hasConceptScore W1489304851C99454951 @default.
• W1489304851 hasIssue "2" @default.
• W1489304851 hasLocation W14893048511 @default.
• W1489304851 hasLocation W14893048512 @default.
• W1489304851 hasOpenAccess W1489304851 @default.
• W1489304851 hasPrimaryLocation W14893048511 @default.
• W1489304851 hasRelatedWork W1531674964 @default.

• next